- Sebastian Herzog as Chief Operating Officer responsible for Production, Quality, Supply Chain, Engineering, Operational Excellence and Logistics
- Finance and IT led by Matthias Dittmer
Warngau, Germany, November 28, 2023
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced the expansion of its leadership team to implement its strategic growth strategy. Following Philipp Karbach taking over the role of Chief Executive Officer (CEO) in June this year, Sebastian Herzog now strengthens the management team with his many years of industry expertise in the role of Chief Operating Officer (COO). Finance expert Matthias Dittmer takes over the Finance and IT department as Vice President.
Sebastian Herzog is heading the Operations division as COO since April 2023, driving the strategic expansion of the AMW site in Warngau. His area of responsibility includes Manufacturing, Quality, Supply Chain, Engineering, Operational Excellence and Logistics. As an experienced executive with global expertise in the chemical-pharmaceutical and consumer health industries, he has shaped transformation processes in various companies, including the Ontex Group, Grünenthal GmbH and Bayer AG. Throughout his career, he gained significant experience in the areas of lean manufacturing, supply chain, project engineering and quality. Mr. Herzog holds a Master of Business Administration in Production Management from Koblenz University of Applied Sciences as well as education and training degrees in engineering and chemical process engineering.
Matthias Dittmer, Vice President Finance and IT, assumed responsibility for this area in October 2023. In his previous positions, including at Eurofins Scientific, TE Connectivity and Sirona Dental Systems, he gained extensive experience in controlling and financial group reporting as well as implementing ERP systems in complex, highly regulated industries with international structures. Mr. Dittmer holds a degree in economics from Ludwig-Maximilians-University in Munich, Germany.
“AMW has set itself high goals. In addition to making our approved products goserelin and leuprorelin globally available, these goals include the expansion of production capacities while simultaneously increasing customer satisfaction. We are therefore extremely pleased to have Sebastian Herzog as a very experienced professional on board. We are convinced that under his leadership the development of a benchmark factory meeting international standards will make a significant contribution to the progression of our company in the coming years,” said Philipp Karbach, CEO of AMW. “Furthermore, I am delighted to welcome Matthias Dittmer as Vice President Finance and IT in this decisive stage. With his extensive experience, especially in financial controlling, he will support the strategic course of our management team and implement process optimizations. With these recent personnel additions, we are well on our way to achieving our goal of providing patients and our partners with value-added medicines for improved medication adherence and cost-effective therapies.”
AMW GmbH is a specialty pharmaceutical company focused on biodegradable sustained-release drug delivery systems, providing patients and partners access to value-added medicines and cost-effective therapies. Based on its technology platform, the Company builds on a growing own and partnered development pipeline. AMW has two approved products, goserelin and leuprorelin implants, which are distributed worldwide through both local and global pharma partners. In Germany, leuprorelin is marketed as Leugon® by AMW’s wholly owned subsidiary Endomedica GmbH. To support pharma and biotech partners in the development and manufacturing of their products and life-cycle solutions, AMW uses its leading-edge formulation development expertise.
AMW is based in Warngau near Munich, Germany.
For further information, please contact:
Phone: +49 8024 470999-0